Searchable abstracts of presentations at key conferences on calcified tissues
Previous issue | Volume 5 | ECTS2016 | Next issue

43rd Annual European Calcified Tissue Society Congress

Rome, Italy
14 May 2016 - 17 May 2016

Card image cap

Poster Presentations

Osteoporosis: treatment

ba0005p379 | Osteoporosis: treatment | ECTS2016

Clinical features of atypical femur fracture

Ho Moon Kyoung , Sup Shin Joong , Chul Kim Nak

Introduction: The correlation between the occurrence of atypical femur fractures (AFFs) and prolonged bisphosphonate use has been reported in many studies. However, the incidence of AFFs is extremely low, which results in the lack of studies illuminating its treatment and clinical results so far. In this study, we aim to elucidate the clinical outcomes of bisphosphonate-associated AFFs and the clinical results depending on the bisphosphonate therapy period.<p class="abstex...

ba0005p380 | Osteoporosis: treatment | ECTS2016

Postmenopausal osteoporosis tolerance and efficacy of different therapeutic protocols

Nassar Kawtar , Janani Saadia , Rachidi Wafae , Mkinsi Ouafa

Introduction: Osteoporosis is the most common bone disease embrittling. Prevention and treatment strategies are well defined and are always updated. The therapeutic decision is based on the individual risk of fracture, effectiveness and therapeutic tolerance. However, side effects attributed to treatment may exist. Thus, the benefit and risks of prescription drugs is optimized by the choice of the right time and the right treatment.The objective of the s...

ba0005p381 | Osteoporosis: treatment | ECTS2016

Treatment outcomes during teriparatide use in Greece: country sub-analysis of the Exfos Observational Study

Aloumanis Kyriakos , Savvidis Matthaios , Repousis Alexandros-Paris , Lianou Helen , Drossinos Vangelis , Kapetanos George

Scope: Extended Forsteo Observational Study (ExFOS), a multinational, non-interventional, prospective, observational study aims to evaluate fracture outcomes, back pain (BP), compliance and health-related Quality of Life (QoL) in osteoporotic patients prescribed teriparatide (TPTD). We present treatment outcomes for patients (male or female) treated for up to 24 months in Greece.Methods: Of the 440 patients enrolled in the study 416 (mean age 69.9±9...

ba0005p382 | Osteoporosis: treatment | ECTS2016

Effects of single bolus injection of vitamin D on serum FGF23, Sclerostin and DKK1 concentrations in vitamin D-deficient subjects

Dong Jang Dong , Choi Hoon , Lim Sung-Kil

Objective: Bone is one of endocrine organ and osteocytes secretes FGF23, Sclerostin and DKK1. FGF23 inhibits renal phosphate reabsorption and suppresses 1-α hydroxylase activity. Calcitriol stimulates FGF23 synthesis in bone. We aimed to determine the effect of single bolus injection of vitamin D on serum FGF23, DKK1 and Sclerostin concentrations in vitamin D-deficient subjects.Design and methods: The study group was composed of placebo group with s...

ba0005p383 | Osteoporosis: treatment | ECTS2016

A interventional study in a real life setting to assess the clinical efficacy and effect to fracture in the 1 year after the injection of zoledronic acid in osteoporotic patients with long bone or spine, pelvic fractures

Lee Jaewon , Kim Joonguk , Park Ki-chul , Park Ye-Soo

Objectives: There are some studies that evaluated changes of bone marrow density (BMD) and re-fracture after zoledronic acid injection. However, there is no study that showed about the fracture on all of the body, fracture healing, and improvement of clinical symptom after zoledronic acid injection. In this study, authors evaluated the 1 year BMD change, changes of lumbar pain in lumbar spine fractures, effects on fracture healing, re-fracture and additional fracture on other ...

ba0005p384 | Osteoporosis: treatment | ECTS2016

Magnesium together with Calsium and vitamin D improves the bone metabolism in (70y) healtly females

Bohmer Thomas , Wang Grethe , Hoiseth Arne

Background: In the National Osteoporosis Guide 2014 all the patients are first recommended adequate calcium and vitamin D intake. For additional treatment US FDA approves the use of medications within seven different drug groups, but no magnesium. We have therefore studied the beneficial effect of Mg added to a Ca/vitamin D regime.Study: Fifty healthy women aged above 70 years recruited from elderly center were randomized into a Mg supplementation group ...

ba0005p385 | Osteoporosis: treatment | ECTS2016

The effect of teriparatide on fracture healing of vertevral compression fracture in postmenopausal women

Young Park Si , Woo Suh Seung , Young Hong Jae , Rae Kim Jung

Introduction: Acute vertebral compression fractures cause severe back pain and need long time to heal. The progression of fracture or nonunion is not rare. The teriparatide is a synthetic parathyroid hormone which has been used as anabolic agent and treatment of osteoporosis. It can also be used for promoting fracture healing in special condition. Periodic infusion of teriparatide enhances bone formation and increases bone strength. We evaluated the effect of periodic teripara...

ba0005p386 | Osteoporosis: treatment | ECTS2016

Atypical femoral fractures after long-term bisphosphonates therapy: case report

Galesanu Corina , Buzduga Catalin , Florescu Alexandru , Zaharia Valentin , Lisnic Vasile

Introduction: Bisphosphonates are the most commonly prescribed type of medication for the treatment of osteoporosis. This treatment, however, is not without adverse effects. Several case reports and case series have indicated an association between a unique fracture type, so-called ‘atypical femoral fractures,’ (AFF) and prolonged bisphosphonate use.Case report: We present a 77-year-old woman with no history of trauma, or associated with low-en...

ba0005p387 | Osteoporosis: treatment | ECTS2016

Effect of 61-week administration with beta-hydroxy-beta-methylbutyrate on volumetric bone mineral density of lumbar spine in osteoporotic patient

Tatara Marcin , Krupski Witold , Majer-Dziedzic Barbara

Currently available osteoporosis treatment include antiresorptives and/or anabolic agents. Studies in animals have shown that beta-hydroxy-beta-methylbutyrate (HMB) administration affects anabolically bone tissue metabolism and improves morphological, densitometric and mechanical properties of bones in axial and appendicular skeleton. Thus, the aim of the study was to present first data on effects of 61-week treatment with HMB on volumetric bone mineral density (vBMD) of lumba...

ba0005p388 | Osteoporosis: treatment | ECTS2016

AMD3100 improves ovariectomy-induced osteoporosis in mice by facilitating mobilization of hematopoietic stem/progenitor cells

Min Woo-Kie , Hwan Kim Jin

Inhibition of an increase of osteoclasts has become the most important treatment for osteoporosis. The CXCR4 antagonist, AMD3100, plays an important role in the mobilization of osteoclast precursors within bone marrow (BM). However, the actual therapeutic impact of AMD3100 in osteoporosis has not yet been ascertained. Here we demonstrate the therapeutic effect of AMD3100 in the treatment of ovariectomy-induced osteoporosis in mice. We found that treatment with AMD3100 resulted...

ba0005p389 | Osteoporosis: treatment | ECTS2016

Hypercalcemia after discontinuation of long-term denosumab treatment

Langdahl Bente , Harslof Torben , Kaal Andreas , Rejnmark Lars , Sophie Solling Anne

Purpose: Denosumab is commonly used as an anti-resorptive agent to treat osteoporosis. After discontinuation of denosumab, however, bone resorption increases again, and the bone mass gained during therapy is lost within a year.Methods: We present a case report of asymptomatic hypoparathyroid hypercalcemia in a patient who discontinued long-term treatment with denosumab.Results: A 67-year old women with osteoporosis was treated with...

ba0005p390 | Osteoporosis: treatment | ECTS2016

Denosumab therapy results in a high frequency of responders by bone mineral density in both treatment-naïve patients and patients switching therapies

Almohaya Mohammed , Liu Angela , Kendler David

Clinical trials suggest that denosumab (DEN) therapy results in greater increases in bone mineral density (BMD) in treatment-naive patients than in patients switched from bisphosphonates.We retrospectively reviewed charts of all patients treated with DEN at an osteoporosis referral centre in Vancouver, Canada including all patients treated with DEN 60 mg SC every 6 months for 1 year or more, and in whom baseline and follow-up BMDs were available. BMD was...

ba0005p391 | Osteoporosis: treatment | ECTS2016

Prevalence of osteoporosis and effectiveness of screening test using ultrasound bone densitometry and education in a community-dwelling population

Ha Yong-Chan , Kim Deog-Yoon , Lee Young-Kyun , Cho Eun-Hee , Kwon Gi-Doo

Background: In 2004, we reported a 48.1% prevalence of osteoporosis in an Ibansung cohort. The current prospective intervention study was undertaken in order to estimate the prevalence of osteoporosis from 2004 to 2015 and the increasing treatment rate of osteoporosis following osteoporosis screening tests with ultrasound bone densitometry and education in the same cohort.Methods: From November 1, 2014 to August 31, 2015, 960 adults ≥50 years of ag...

ba0005p392 | Osteoporosis: treatment | ECTS2016

The effect of oral dabigatran etexilate on bone density, strength, and microstructure in female and male mice

Bo Brent Mikkel , Skovhus Thomsen Jesper , Bruel Annemarie

Pradaxa (dabigatran etexilate) is a new anticoagulant, which recently has been approved for clinical use. Dabigatran etexilate (DE) is a direct thrombin inhibitor, which in addition to its effect on blood clotting, may have an anabolic effect on bone. Recently, it has been reported that DE could significantly reduce bone resorption and enhance bone formation resulting in a significant and substantial increase in trabecular bone mass in mice.The aim of th...

ba0005p393 | Osteoporosis: treatment | ECTS2016

Long-term high-dose resveratrol supplementation reduces bone mass and strength in rats

Juul Ornstrup Marie , Bruel Annemarie , Skovhus Thomsen Jesper , Harslof Torben , Lomholt Langdahl Bente , Bonlokke Pedersen Steen

Background: Resveratrol (RSV), a natural polyphenolic compound, stimulates osteoblasts and inhibits osteoclast activation in vitro. Conflicting results have emerged from short-term studies in rodents but a recent study in men suggests a positive effect on BMD.Aim: To evaluate effects of short- and long-term high-dose RSV supplementation on bone in immobilized and non-immobilized rats.Methods: A total of 72 female Wistar ra...

ba0005p394 | Osteoporosis: treatment | ECTS2016

Inhibitory effects of nanopartical calcium administration on dexamethasone-induced osteoporosis development in axial skeleton of pigs

Tymczyna Barbara , Tatara Marcin , Tymczyna-Sobotka Monika , Krupski Witold , Szabelska Anna

The aim of the study was to evaluate effects of 6-month-long administration with nanopartical calcium on morphological and densitometric properties of axial skeleton in pigs subjected to osteoporosis induction with dexamethasone. Male newborn piglets (N=28) were divided after birth into four equal groups (control group receiving placebo, Dex group receiving dexamethasone, NanoCa group receiving orally nanopartical calcium and NanoCa/Dex group) receiving simultaneously...

ba0005p395 | Osteoporosis: treatment | ECTS2016

Acute kidney injury after a single intravenous zoledronic acid administration in patients with osteoporosis

Cipriani Cristiana , Clementelli Carolina , Fassino Valeria , Manai Rizieri , Danese Vittoria , Cecchetti Veronica , Ferrone Federica , Pepe Jessica , Minisola Salvatore

Safety data on zoledronic acid (ZA) administration for osteoporosis suggest potential kidney toxicity; indeed, it is not indicated in patients with impaired renal function. Patients’ clinical monitoring usually includes glomerular filtration rate (GFR) evaluation; no study addressed the issue of the early kidney injury. We evaluated the early (within 3 months) effect of iv ZA on renal function defining the potential role of AKI biomarkers in unveiling subtle damage.<p...

ba0005p396 | Osteoporosis: treatment | ECTS2016

Oral health assessment necessary with comprehensive geriatric assessment

Gupta Siddarth , Gupta Abhaya

Objective: Good oral health is important for well being especially in the elderly. Osteonecrosis of Jaw is rare side effect of bisphosphonates and Denosumab. Patients need adequate dental precautions and appropriate advice from doctors and dentists to reduce the chance of this condition. Aim of the study was to assess the dental health of patients with osteoporotic fractures receiving bisphosphonate or denosumab treatments.Methods: Single person administ...

ba0005p397 | Osteoporosis: treatment | ECTS2016

Evaluating dental health risk assessment amongst bisphosphonate users

Gupta Siddarth , Gupta Abhaya

Objective: With increasing usage of bisphosphonates and increasing longevity, many elderly patients are on long term bisphosphonates and may require some dental procedure. We wanted to determine the dental risk status based on Scottish guidance for Dental practitioners 2011.Methods: An interviewer recorded information needed to classify risk status amongst a randomly selected database of bisphosphonate users.Setting: Teaching hospi...

ba0005p398 | Osteoporosis: treatment | ECTS2016

Dementia and hip fractures-

Gupta Saloni , Pansari Kalpana , Gupta Abhaya

Objective: From April 2012, pre- and post-operative cognitive assessment amongst hip fracture patients is one of the criteria for enhanced payment to hospitals in England in UK. Aim of the study was to assess the prevalence of dementia amongst hip fractures and assessments from specialist mental health services.Methods: Prospective study.Setting: Acute hip unit at a UK hospital in Wales(not England).Subjects:...

ba0005p399 | Osteoporosis: treatment | ECTS2016

Need for integrated proactive approach for dementia and hip fracture care

Gupta Saloni , Pansari Kalpana , Gupta Abhaya

Objective: From April 2012, pre- and post-operative cognitive assessment amongst hip fracture patients is one of the criteria for enhanced payment to hospitals in England in UK. Aim of the study was to assess the association between dementia and hip fracturesMethods: Setting – Acute hip unit at a UK hospital in Wales (not England).Subjects – patients admitted following hip fracturesA single research...

ba0005p400 | Osteoporosis: treatment | ECTS2016

The upper two third of the reference interval of the serum calcium level is required for the optimal increase in lumbar bone mineral density by bisphosphonate and active vitamin D3 analogue for osteoporosis

Kinoshita Mayuko , Ishijima Muneaki , Kaneko Haruka , Lizu Liu , Sadatsuki Ryo , Hada Shinnnosuke , Yusup Anwar , Arita Hitoshi , Shiozawa Jun , Yamanaka Makoto , Sakamoto Yuko , Nojiri Hidetoshi , Kaneko Kazuo

Background: It is important to increase bone mineral density (BMD) by the treatment with bisphosphonates (BPs), as lower BMD has been revealed to be one of the risk factors for the subsequent fragility fracture in patients with osteoporosis treated with BPs.Methods: The two independent populations of the patients with postmenopausal osteoporosis who were treated for 2y by BPs with active vitamin D analogue (aVD) were enrolled in Study 1 (n=93) a...

ba0005p401 | Osteoporosis: treatment | ECTS2016

Two-fold regional variation in initiation of anti-osteoporosis medication after hip fracture in the UK

Shah Anjali , Prieto-Alhambra Daniel , Hawley Samuel , Delmestri Antonella , Lippett Janet , Cooper Cyrus , Judge Andrew , Javaid Kassim

Objective: Describe UK regional variation in prescription of anti-osteoporosis drug therapy before and after a primary hip fracture during 1999–2013.Materials and Methods: We used primary care data (Clinical Practice Research Datalink) to identify patients with a hip fracture and primary-care prescriptions of any anti-osteoporosis drugs (bisphosphonates, strontium, denosumab, oestrogen therapy, SERMS, teriparatide) prior to primary hip fracture and ...

ba0005p402 | Osteoporosis: treatment | ECTS2016

Is recovery of lactation-induced bone loss influenced by immobilization in mice?

Givskov Sorensen Thomas , Bruel Annemarie , Skovhus Thomsen Jesper

Lactation in both humans and mice is associated with a substantial bone loss, in mice this bone loss is recovered within 4 weeks after weaning. This recovery is considered to be the most rapid physiological bone formation in adult life. The aim of the study was to investigate the effect of the post-lactational anabolic response on a disuse bone loss induced by Botulinum toxin (BTX).Forty-eight NMRI mice were divided into the following groups: pregnan...

ba0005p403 | Osteoporosis: treatment | ECTS2016

Biochemical monitoring of teriparatide efficacy in a real world setting

Pigott Thomas , Eastell Richard , Peel Nicola

Teriparatide is an anabolic agent given to reduce fracture risk in osteoporosis; it increases BMD and bone turnover. For monitoring treatment efficacy, serum PINP shows the greatest increase and low variability; it has been proposed as a marker of individual treatment response. We aimed to evaluate the utility of PINP to monitor teriparatide treatment in clinical practice.We performed a retrospective evaluation of 91 patients treated with teriparatide si...

ba0005p404 | Osteoporosis: treatment | ECTS2016

IV. zoledronic acid promotes healing of complicated stress fractures in the foot

Fink Eriksen Erik , Ianssen Torben , Elling Husebye Elisabeth

Delayed healing of stress fractures constitutes a significant clinical problem causing prolonged pain and disability for the patients affected. All stress fractures exhibit Bone Marrow (edema) Lesions (BMLs) with and without fracture lines on MRI, and in cases of delayed union these lesions persist. Previous studies on transient osteoporosis and osteoarthritis have demonstrated that bisphosphonates can reduce BMLs. We therefore wanted to test, whether treatment with iv. zoledr...

ba0005p405 | Osteoporosis: treatment | ECTS2016

Lithium chloride enhances bone formation and implant osseointegration in osteoporotic condition

Jin Yifan , Zhang Hualin Zhang , Hu Xiaohui , Wu Gang , Dong Yiwen , Deng Zhennan , Huang Shengbin , Pathak Janak L , Liu Jinsong

Osteoporotic patients have poor bone quality and high risk of dental and orthopaedic implant failure. Lithium chloride (LICl) has been reported to enhance osteogenesis. However, the role of LiCl in bone formation and implant osseointegration in osteoporotic condition is still unknown. Therefore, we aimed to investigate the effect of LiCl on bone formation and implant osseointegration in osteoporotic rats.Three months old Sprague–Dawley female rats (...

ba0005p406 | Osteoporosis: treatment | ECTS2016

Adherence and persistence to teriparatide treatment in patients attending a specialised Bone Health Service

Steen Georgina , Maher Niamh , Fallon Nessa , Dillon Aoife , Mahon James , Lannon Rosaleen , McCarroll Kevin , Walsh J B , Casey Miriam

Introduction: Osteoporosis affects the bones causing weak or brittle bones and increasing the risk of fracture. Efficacy of anti-osteoporotic treatment is based on drug potency and adherence and persistence. Teriparatide (TPTD) is the first anabolic agent developed for the treatment of osteoporosis. It is usually given as a daily subcutaneous injection for a two-year treatment course.Aim: To evaluate adherence and persistence to TPTD treatment in patient...

ba0005p407 | Osteoporosis: treatment | ECTS2016

Impact of 3-year vitamin D and calcium supplementation on mineral and organic matrix formation of trabecular bone in postmenopausal osteoporosis

Paschalis E P , Gamsjaeger S , Hassler N , Fahrleitner-Pammer A , Dobnig H , Stepan J J , Eriksen E F , Klaushofer K

Clinical trials involving drug therapies for postmenopausal osteoporosis typically compare effects of the active drug combined with vitamin D (vit D) and calcium (Ca) vs vit D and Ca supplementation on its own. Bone strength is estimated based on the amount of bone, frequently expressed as bone mineral density determined by dual X-ray absorptiometry, and quality of bone, hardly measured in clinical practice.The purpose of the present study was to compare...

ba0005p408 | Osteoporosis: treatment | ECTS2016

Treat-to-target in osteoporosis. Mith or reality? Results of a Spanish Delphi study

Munoz-Torres Manuel , Casado Enrique , Jodar Esteban , Nogues Xavier , Nolla Joan Miquel , Quesada-Gomez Jose Manuel , Canals Laura , Balcells Monica , Lizan Luis

Objective: To define, by expert consensus, the criteria for the application of a Treat-to-Target (T2T) strategy in osteoporosis, in Spain, and to assess the adequacy of current treatments for it.Material and methods: Six Spanish experts in osteoporosis formed the Scientific Committee that led the project and designed the questionnaire used in two Delphi rounds. The 24 items included in the questionnaire assessed the experts’ wish (W) and prognosis (...

ba0005p409 | Osteoporosis: treatment | ECTS2016

Atypical femur fracture in an adolescent with X-linked osteoporosis based on PLS3 mutation

van de Laarschot Denise M , Zillikens M Carola

Background: Long-term use of bisphosphonates has raised concerns about the association with Atypical Femur Fractures (AFFs) that have been reported mainly in postmenopausal women.Clinical case: An 18-year-old patient with juvenile osteoporosis based on X-linked osteoporosis due to a PLS3 mutation developed a low trauma femoral fracture after seven years of intravenous and two years of oral bisphosphonate use, fulfilling the revised ASBMR diagnostic crite...

ba0005p410 | Osteoporosis: treatment | ECTS2016

Can bone turnover markers help to define the duration of bisphosphonate drug holidays?

Statham Louise , Aspray Terry , Abdy Sharon

Background: On cessation of bisphosphonate treatment, while bone mineral density decreases slowly, bone resorptive markers such as C-terminal telopeptide (CTX) increase more quickly and may be useful in monitoring ‘offset’ of action. Our aim was to analyse changes in CTX on stopping long-term bisphosphonate treatment to guide clinical decision-making on the duration of treatment cessation (‘drug holidays’).Subjects and methods: A tota...

ba0005p411 | Osteoporosis: treatment | ECTS2016

Establishment of a large sector-spanning fracture liaison service in Germany

Wolters Wanja , Rossmann Markus , Pommerening Jonas , Dahmen Georg P , Schusseler Andreas , Bullmann Catharina , Weber Ingrid , Ott Nils , Lehmann Wolfgang , Hesse Eric

Patients with osteoporotic fractures are frequently treated in trauma surgery. While fracture fixation is at the center of patient care, treatment of the underlying bone disorder is often not considered, thereby increasing the risk for subsequent fractures. Closing this treatment gap is therefore among the greatest challenges in modern trauma surgery. To address this problem, we established a fully structured, multidisciplinary, sector-spanning fracture liaison service (FLS), ...

ba0005p412 | Osteoporosis: treatment | ECTS2016

The value of the central vertebral height restoration by kyphoplasty for treatment of biconcave vertebral compression fractures

Zhang Jia , Li Qiang , Zhu Sheng

Purpose: To study the value of the central vertebral height restoration by kyphoplasty for treatment of biconcave vertebral compression fractures.Method: Review the patients with the single biconcave vertebral compression fracture receiving kyphoplasty treatment from 2006 to 2013 (49 cases, 13 males and 36 females) According to Genant classification, with the central vertebral compression ratio, they are divided into type II (<25%, 11 cases), type II...

ba0005p413 | Osteoporosis: treatment | ECTS2016

Dose postoperative applications of diphosphonate medicine at an early stage have influence on union of fracture?

Li Qiang , Zhang Jia , Zhu Shen

Background: Surgical and conservative treatments are both crucial method to deal with osteoporotic fracture, anti-osteoporotic therapy is the most important among conservative treatments and diphosphonate medicine is the first-line choice. The pharmacological action of diphosphonate medicine is to inhibit the function of osteoclast, so there is no consensus if it will inhibit porosis and union of fracture.Purpose: To find out the influence of diphosphona...

ba0005p414 | Osteoporosis: treatment | ECTS2016

Teriparatide reduces the risk of vertebral fractures compared with standard care in patients with severe osteoporosis

Riches Philip , Calero Ismael , Ralston Stuart

Objectives: Treatment outcomes in patients treated with teriparatide were compared to standard care in patients with severe osteoporosis (bone mineral density T score of −4 or less).Methods: An observational study was performed of patients attending a specialist osteoporosis service and who were initiated on teriparatide (n=324). Patients that met criteria for teriparatide but declined treatment, were already established on a bisp...

ba0005p415 | Osteoporosis: treatment | ECTS2016

rs72658163, a new heterozygous variant in COL1A2 associated with atypical femoral fracture

Funck-Brentano Thomas , Ostertag Agnes , Debiais Francoise , Fardellone Patrice , Collet Corinne , Mornet Etienne , Cohen-Solal Martine

Atypical femoral fractures (AFF) of the subtrochanteric region are rare. Bisphosphonates account to a large extent to their occurrence, however AFF also occur without exposure to bone medication. We here assessed the genetic factors associated with AFF among subtrochanteric fractures. Cases of subtrochanteric or femoral shaft fractures were identified through ICD-10 codes in three French academic centers from 2007 to 2010. Medical records were analyzed by two investigators tha...

ba0005p416 | Osteoporosis: treatment | ECTS2016

Hydrogen sulfide is a novel regulator of bone formation involved in the bone loss induced by estrogen deficiency

Gambari Laura , Malik Tiagy Abdul , Lisignoli Gina , Pacifici Roberto , Grassi Francesco

Hydrogen sulfide (H2S) is a gaseous molecule produced endogenously in mammalian cells. H2S was recently found to play important roles in the regulation of inflammation, redox homeostasis and cell lifespan. Moreover, H2S was shown to maintain mesenchymal stem cell (MSC) function and stimulate osteogenic differentiation of MSC. However, it is unclear whether H2S plays any role in the bone loss induced by estrogen deficiency.<p clas...

ba0005p417 | Osteoporosis: treatment | ECTS2016

The fate of injected cement after percutaneous vertebroplasty

Hwan Kim Jin , Hwa Yoon Hyung , Kie Min Woo

Introduction: Percutaneous vertebroplasty is a well known surgical method to put the bone cement at osteoporotic vertebrae. There was a few report concerning about bone cement related complication such as dislodgment of injected cement. There are some contradictory study for long term reaction to bone cement in osteoporotic bone, especially injected cement features. This study is to assess the radiographic features of patients who underwent percutaneous vertebroplasty (PVP) in...

ba0005p418 | Osteoporosis: treatment | ECTS2016

Globular adiponectin reverses trabecular osteopenia in ovariectomized rats

Pal China Shyamsundar , Porwal Konica , Kushwaha Sapana , Gurjar Anagha , Singh Abhishek , Sanyal Sabyasachi , Chattopadhyay Naibedya

Adiponectin has recently been shown to influence skeletal metabolism. Over-expression of adiponectin gene suppresses bone resorption and increases trabecular bone mass. Bone marrow stromal cells from adiponectin-null mice had reduced mineralized nodule formation ability compared with wild type mice. Adiponectin, signalling via the adiponectin receptor 1 (AdipoR1) stimulates osteoblast differentiation and inhibits osteoclastogenesis. We have shown that the globular for...